China’s 2026 AINV guideline brings whole-course nausea control into routine oncology care
Anticancer therapy-induced nausea and vomiting remains one of the most disruptive toxicities in oncology, not because it is rare, but because it erodes adherence, nutrition, hydration, sleep, and the patient’s willingness to continue treatment. The 2026 CACA guidelines for the prevention and control of nausea and vomiting induced by anticancer therapy respond to that problem with a China-specific framework built for adults across systemic drug therapy, radiotherapy, surgery, and other anticancer settings.
The document was developed by the Committee of Neoplastic Supportive-Care of the China Anti-Cancer Association using the GRADE evidence system and the Delphi method. Its structure moves beyond a narrow antiemetic list and instead organizes care around the full clinical course: risk assessment, regimen selection, breakthrough symptoms, anticipatory nausea, refractory disease, adverse-effect monitoring, and follow-up in day-care wards. In practical terms, the guideline treats nausea and vomiting as a longitudinal supportive-care problem rather than a single premedication decision.
A single emesis episode can unravel an otherwise well-tolerated treatment plan.
Multi-pathway biology drives the need for layered prevention
The guideline places heavy emphasis on the biology of anticancer therapy-induced nausea and vomiting, and for good reason. Emesis emerges from overlapping peripheral and central pathways, with the peripheral 5-HT3 receptor and central NK1 receptor serving as core pharmacologic targets. Chemotherapy, radiotherapy, and perioperative stress can trigger serotonin release, activate vagal afferents, and engage central emetic circuitry. Once those signals converge, a single agent is rarely enough for higher-risk regimens.
This is why the guideline favors stepwise, mechanism-based prophylaxis. It does not frame antiemesis as a generic add-on, but as a biologically matched intervention designed to blunt the signaling cascade before symptoms become established. For clinicians, that means the regimen risk and the patient’s own vulnerability both matter. Prior nausea, poor oral intake, anxiety, dehydration risk, and previous treatment intolerance can shift the threshold for more intensive prophylaxis even when the regimen itself is not at the top of the emetogenic scale.
Dynamic risk assessment replaces one-size-fits-all premedication
One of the clearest advances in the 2026 edition is the recommendation for dynamic comprehensive assessment. Rather than relying on regimen emetogenicity alone, the guideline calls for combining treatment-related risk with individual patient factors. That approach better reflects the real world, where two patients receiving the same regimen may experience very different symptom burdens.
The guideline’s visual decision tree is built around this principle. It integrates accessible innovative drugs in China and offers stepwise medication pathways for different treatment contexts, including systemic drug therapy, radiotherapy, and surgery. For clinicians at the bedside, the value lies in speed and consistency: the pathway is intended to help teams move from risk stratification to specific prophylactic choices without forcing every decision into an improvised local practice pattern.
Day-care oncology settings are especially important here. Many patients now receive anticancer treatment in outpatient or short-stay environments, where nausea control has to be established before discharge and reinforced afterward. The guideline explicitly extends its attention to pre-treatment and follow-up in day-care wards, acknowledging that a patient who leaves the unit with incomplete symptom control can quickly spiral into rescue medication use, delayed nutrition, missed doses, or unplanned return visits.
Breakthrough, refractory, and anticipatory symptoms receive separate pathways
The document gives distinct management pathways to breakthrough, refractory, and anticipatory AINV, which is clinically important because these syndromes reflect different points of failure. Breakthrough symptoms imply insufficient prophylaxis or an unexpectedly strong emetic stimulus. Refractory symptoms suggest failure of the initial strategy across subsequent exposures. Anticipatory nausea, by contrast, is often conditioned by prior bad experiences and may persist even before treatment starts, making psychological and environmental triggers part of the clinical problem.
Separating those entities prevents a common mistake in oncology practice: escalating therapy indiscriminately without identifying why the first plan failed. The guideline’s structure encourages a more disciplined response, with rescue therapy, regimen revision, and supportive measures matched to the symptom pattern rather than a reflexive repeat of the same approach. That is especially relevant in patients with repeated cycles of treatment, where fear of nausea can become as disabling as the nausea itself.
Chinese practice factors are built into the preventive framework
A notable feature of the 2026 guideline is the inclusion of non-pharmacological interventions such as acupuncture and dietary measures. Their presence reflects local clinical practice and broadens the prevention strategy beyond drug therapy alone. Dietary modification may help patients preserve oral intake when appetite is fragile, while acupuncture is presented as part of a culturally familiar supportive-care toolkit rather than as a replacement for pharmacologic prophylaxis.
The guideline also addresses management of adverse drug reactions linked to NK1 receptor antagonists, 5-HT3 receptor antagonists, olanzapine, and other antiemetic drugs. That inclusion matters because supportive care often fails not from lack of efficacy, but from intolerance, sedation, constipation, QT-related concerns, or drug-drug interaction problems that complicate continued use. A preventive pathway only works if clinicians can recognize and respond to those safety issues early.
Team-based care and quality control move antiemesis into system design
The guideline broadens its scope well beyond medication selection. It calls for clearer criteria for initiating multidisciplinary collaboration and promotes integrated patient-nurse-doctor alliances. In practice, that kind of coordination is essential because nausea and vomiting sit at the intersection of oncology, nursing assessment, pharmacy review, nutrition, and patient education. A prescription written in clinic will not succeed if the patient cannot understand when to start the medication, what to do when symptoms break through, or when to call for help.
Quality control also receives explicit attention through core indicators. That signals a move toward measurable supportive care rather than informal reassurance. If a hospital can track whether prophylaxis was started on time, whether breakthrough symptoms were documented, and whether follow-up occurred after treatment, then AINV management becomes auditable and improvable. The result is not merely better symptom control on paper; it is a more reliable pathway for treatment completion in adults receiving anticancer therapy.
The guideline is explicit that it applies to adults and excludes children, leaving pediatric antiemetic management outside its scope. Its most immediate contribution is practical standardization: a China-specific, evidence-based framework that aligns mechanism, regimen risk, patient risk, rescue care, and safety monitoring into one coordinated approach. The unresolved challenge is implementation fidelity. A guideline can define the pathway, but clinical benefit depends on whether oncology teams can apply it consistently across wards, outpatient units, and follow-up settings, especially when symptom burden escalates between visits.